Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Rating of "Moderate Buy" from Brokerages

Key Points

• Xeris Biopharma Holdings, Inc. received a consensus rating of "Moderate Buy" from six analyst firms, with a twelve-month average target price of $6.58.
• Insider transactions included Kevin Mcculloch buying 25,000 shares at $4.38 each, while Director John Johnson sold 107,500 shares at an average price of $7.32.
• The company recently reported an EPS of ($0.01) for the last quarter, exceeding analyst estimates, with revenues of $67.71 million.

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) has been given an average rating of "Moderate Buy" by the six ratings firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $6.5833.

A number of equities research analysts recently issued reports on XERS shares. Wall Street Zen upgraded Xeris Biopharma from a "hold" rating to a "strong-buy" rating in a research note on Saturday, August 9th. Oppenheimer lifted their target price on shares of Xeris Biopharma from $6.00 to $7.00 and gave the stock an "outperform" rating in a research note on Friday, May 9th. Finally, HC Wainwright started coverage on shares of Xeris Biopharma in a report on Tuesday, August 12th. They set a "buy" rating and a $10.00 target price on the stock.

Xeris Biopharma Price Performance

Shares of Xeris Biopharma stock traded up $0.02 on Friday, reaching $7.59. 1,563,406 shares of the company traded hands, compared to its average volume of 3,305,232. The company has a 50 day moving average of $5.47 and a 200 day moving average of $4.82. Xeris Biopharma has a 52 week low of $2.48 and a 52 week high of $7.79. The firm has a market capitalization of $1.23 billion, a PE ratio of -36.14 and a beta of 0.65.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.02. The firm had revenue of $67.71 million during the quarter, compared to the consensus estimate of $64.58 million. As a group, analysts anticipate that Xeris Biopharma will post -0.41 earnings per share for the current year.

Insider Buying and Selling at Xeris Biopharma

In related news, Director John Johnson sold 107,500 shares of the business's stock in a transaction that occurred on Wednesday, August 13th. The shares were sold at an average price of $7.32, for a total transaction of $786,900.00. Following the completion of the transaction, the director owned 833,483 shares of the company's stock, valued at approximately $6,101,095.56. The trade was a 11.42% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Dawn Halkuff sold 42,500 shares of the company's stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $7.28, for a total transaction of $309,400.00. Following the sale, the director directly owned 115,000 shares in the company, valued at $837,200. This trade represents a 26.98% decrease in their position. The disclosure for this sale can be found here. Insiders own 6.47% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in XERS. Vanguard Group Inc. grew its position in Xeris Biopharma by 2.7% during the first quarter. Vanguard Group Inc. now owns 8,109,644 shares of the company's stock worth $44,522,000 after buying an additional 210,581 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Xeris Biopharma by 7.2% during the 2nd quarter. Geode Capital Management LLC now owns 3,650,688 shares of the company's stock valued at $17,052,000 after acquiring an additional 244,862 shares during the last quarter. Qube Research & Technologies Ltd grew its holdings in shares of Xeris Biopharma by 67.5% during the second quarter. Qube Research & Technologies Ltd now owns 3,089,771 shares of the company's stock worth $14,429,000 after purchasing an additional 1,245,188 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Xeris Biopharma by 75.4% during the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company's stock worth $15,317,000 after purchasing an additional 1,199,435 shares in the last quarter. Finally, Millennium Management LLC increased its position in shares of Xeris Biopharma by 19.0% in the first quarter. Millennium Management LLC now owns 2,317,972 shares of the company's stock worth $12,726,000 after purchasing an additional 369,420 shares during the last quarter. 42.75% of the stock is currently owned by hedge funds and other institutional investors.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.